Model‐Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer
Clinical and Translational Science · 2026-07 · 19 (7)
DOI: 10.1111/cts.70649 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, online erschienen am 23.06.2026. Verfasst von Xiangyu Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Pharmacometrics, BeOne Medicines, Ltd., San Carlos, California, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Models, Biological. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BeOne Medicines, Ltd.
Abstract (Originalsprache)
Although tislelizumab is approved across multiple malignancies and dosing schedules, intravenous administration imposes logistical burdens. A subcutaneous formulation may improve convenience and reduce resource demands if comparable exposure is achieved. This study evaluated the pharmacokinetics, bioavailability, and injection‐site performance of subcutaneous tislelizumab and used population pharmacokinetic (PopPK) modeling and simulations to support phase 3 dose selection. In the phase 1 BGB‐A317‐103 study, treatment‐naïve patients with locally advanced or metastatic non‐small cell lung cancer received tislelizumab via subcutaneous thigh, subcutaneous abdominal, or intravenous administration. A PopPK model was developed with subcutaneous compartments to characterize site‐specific absorption and covariate effects. Simulations compared subcutaneous 300 mg every 3 weeks (Q3W) with intravenous 200 mg Q3W regimens to estimate the probability of achieving comparable pharmacokinetic exposure. The PopPK model demonstrated greater bioavailability and lower variability with subcutaneous thigh vs. abdominal administration. Estimated absorption rates were 0.189 1/d for thigh and 0.247 1/d for abdomen, with corresponding bioavailability estimates of 86.6% and 73.1%. The model described absorption and exposure across administration routes and supported the simulation of 1,000 trials. Subcutaneous 300 mg thigh administration achieved pharmacokinetic exposures comparable to intravenous 200 mg across key parameters, including trough concentration and area under the curve (AUC) at Cycle 1 and steady state, whereas abdominal administration showed reduced probability of achieving target exposure thresholds for Cycle 1 AUC. Tislelizumab 300 mg Q3W subcutaneous thigh administration is predicted to provide exposure comparable to intravenous 200 mg Q3W, supporting its selection for phase 3 evaluation. Trial registration: ClinicalTrials.gov identifier: NCT06091943.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Pharmacometrics, BeOne Medicines, Ltd., San Carlos, California, USA.
- Department of Clinical Pharmacology and Pharmacometrics, BeOne Medicines, Ltd., Shanghai, China.
- Department of Clinical Development, BeOne Medicines, Ltd., Fulton, Maryland, USA.
- Department of Clinical Development, BeOne Medicines, Ltd., Beijing, China.
- Department of Biostatistics, BeOne Medicines, Ltd., Shanghai, China.
- Department of Scientific Programming, BeOne Medicines, Ltd., Shanghai, China.
ORCID-Profile: Xiangyu Liu, Tian Yu, Nageshwar Budha
Förderung
- BeOne Medicines, Ltd
Zitieren
APA
Liu, X., Guan, Y., Liu, Y., Yu, T., Abdrashitov, R., Niu, Z., Lin, X., Ye, X., Wang, Y., Sahasranaman, S., Hanley, W. D., & Budha, N. (2026). Model‐Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer. Clinical and Translational Science, 19(7). https://doi.org/10.1111/cts.70649
Vancouver
Liu X, Guan Y, Liu Y, Yu T, Abdrashitov R, Niu Z, et al. Model‐Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer. Clinical and Translational Science. 2026;19(7). doi:10.1111/cts.70649
BibTeX
@article{Liu2026,
author = {Liu, Xiangyu and Guan, Ye and Liu, Yixi and Yu, Tian and Abdrashitov, Ramil and Niu, Ziru and Lin, Xiao and Ye, Xiaohan and Wang, Yutong and Sahasranaman, Srikumar and Hanley, William D and Budha, Nageshwar},
title = {Model‐Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {7},
doi = {10.1111/cts.70649}
}
EUVIMED